Geneos Therapeutics – a clinical-stage biotherapeutics company focused on developing personalized therapeutic cancer vaccines (PTCV) – recently announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million.
This funding round adds Shanghai Healthcare Capital (SHC) to Geneos’ investor syndicate. Dr. Jing Bao is joining as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.
GT-30 is evaluating the safety and efficacy of GNOS-PV02 plus plasmid-encoded IL-12 (PTCV) administered in combination with the immune checkpoint inhibitor pembrolizumab in 36 patients with unresectable or metastatic hepatocellular carcinoma (HCC) who progress on or are intolerant to, first-line tyrosine kinase inhibitors (sorafenib or lenvatinib). The study enrollment completed in June of this year with the top-line safety and clinical response data from the complete cohort of 36 patients is anticipated by the end of the year.
KEY QUOTES:
“We are pleased to add SHC to our investor syndicate and Dr. Bao to our team. The depth of knowledge the SHC team brings as well as their network in China will be invaluable to Geneos, especially as we pursue hepatocellular (liver) cancer as our initial target.”
- Niranjan Sardesai, PhD., president and chief executive officer of Geneos Therapeutics
“The results that Geneos has achieved to date in the clinic with its personalized therapeutic cancer vaccine are impressive, and we are pleased to support Geneos’ further clinical development of this important treatment.”
- Jing Bao, MD, partner of SHC
